Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Federation of State Medical Boards. Strategies for Prescribing Opioids for the Management of Pain. Available at https://www.fsmb.org/siteassets/advocacy/policies/strategies-for-prescribing-opioids-for-the-management-of-pain.pdf. Last accessed August 1, 2025.
2. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain: United States, 2022. MMWR Recomm Rep. 2022;71(RR3):1-95.
3. Saffore CD, Tilton ST, Crawford SY, et al. Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. Br J Gen Pract. 2020;70(697):e589-e597.
4. American Medical Association. Opioid Prescriptions Decrease for 10th Consecutive Year. Available at https://end-overdose-epidemic.org/wp-content/uploads/2021/09/IQVIA-opioid-prescription-trends-chart-Sept-2021-FINAL.pdf. Last accessed August 1, 2025.
5. Centers for Disease Control and Prevention. National Vital Statistics System: Provisional Drug Overdose Death Counts. Available at https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Last accessed August 1, 2025.
6. International Narcotics Control Board. Narcotic Drugs, 2024: Estimated World Requirements for 2025. Available at https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2024/Narcotics_2024_EFN.pdf. Last accessed August 1, 2025.
7. Substance Abuse and Mental Health Service Administration. Drug Abuse Warning Network (DAWN): Findings from Drug-Related Emergency Department Visits, 2022. Available at https://library.samhsa.gov/sites/default/files/pep23-07-03-001.pdf. Last accessed August 1, 2025.
8. Louisiana Opioid Surveillance Initiative. Bureau of Health Informatics. Louisiana Department of Health. Opioid Deaths in Louisiana: 2021 Annual Fact Sheet. Available at https://ldh.la.gov/assets/opioid/2021_Annual_Drug_Death_Report.pdf. Last accessed August 1, 2025.
9. Centers for Disease Control and Prevention. Opioid Dispensing Rate Maps. Available at https://www.cdc.gov/overdose-prevention/data-research/facts-stats/opioid-dispensing-rate-maps.html. Last accessed August 1, 2025.
10. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR. 2016;65(1):1-49.
11. Kroenke K, Alford DP, Argoff C, et al. Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med. 2019;20(4):724-735.
12. U.S. Food and Drug Administration. Opioid Analgesic Risk Evaluation and Mitigation Strategies (REMS). Available at https://www.fda.gov/drugs/information-drug-class/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems. Last accessed August 1, 2025.
13. American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25(3):252-264.
14. Whitecar PS, Jonas AP, Clasen ME. Managing pain in the dying patient. Am Fam Physician. 2000;61(3):755-764.
15. O'Brien T, Kane CM. Pain services and palliative medicine—an integrated approach to pain management in the cancer patient.Br J Pain. 2014;8(4):163-171.
16. Breuer B, Fleishman SB, Cruciani RA, Portenoy RK. Medical oncologists' attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011;29(36):4769-4775.
17. Azizoddin DR. Prediction of daily pain and opioid consumption in hospitalized patients with cancer: The importance of psychological symptoms, previous pain, and opioid use. J Clin Oncol. 2022;40(suppl 28):195.
18. Abrahm JL. A Physician's Guide to Pain and Symptom Management in Cancer Patients. 3rd ed. Baltimore, MD: Johns Hopkins University Press; 2014.
19. Dalal S, Bruera E. Assessment and management of pain in the terminally ill. Prim Care Clin Office Pract. 2011;38:195-223.
20. Desbiens NA, Mueller-Rizner N. How well do surrogates assess the pain of seriously ill patients? Crit Care Med. 2000;28(5):1347-1352.
21. Fishman B, Pasteranak S, Wallenstien SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer. 1987;60:1151-1158.
22. UpToDate Lexidrug. Available at https://online.lexi.com. Last accessed August 1, 2025.
23. U.S. Food and Drug Administration. FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-prescription-acetaminophen-products-be-limited-325-mg-dosage-unit. Last accessed August 1, 2025.
24. Manchikanti L, Kaye AM, Knezevic NN et al. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017 ;20(2S):S3-S92.
25. Ducharme J, Moore S. Opioid Use Disorder Assessment Tools and Drug Screening. Mo Med. 2019;116(4):318-324.
26. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442.
27. Opioid Risk Tool. Available at https://nida.nih.gov/sites/default/files/opioidrisktool.pdf. Last accessed August 1, 2025.
28. Butler SF, Budman SH, Fernandez KC, Fanciullo GJ, Jamison RN. Cross-validation of a screener to predict opioid misuse in chronic pain patients (SOAPP-R). J Addict Med. 2009;3(2):66-73.
29. Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1.0-SF. Available at https://www.mcstap.com/docs/SOAPP-5.pdf. Last accessed August 1, 2025.
30. Fine PG, Finnegan T, Portenoy RK. Protect your patients, protect your practice: practical risk assessment in the structuring of opioid therapy in chronic pain. J Fam Pract. 2010;59(9 Suppl 2):S1-S16.
31. DIRE Score: Patient Selection for Chronic Opioid Analgesia. Available at https://amdg.wa.gov/Files/AssessmentTools/11-DIRE_score.pdf. Last accessed August 1, 2025.
32. American Chronic Pain Association. ACPA—Stanford Resource Guide to Chronic Pain Management: 2024 Edition. Available at https://www.acpanow.com/uploads/9/9/8/3/99838302/acpa_stanford_resource_guide_2024.pdf. Last accessed August 1, 2025.
33. Olsen WM, Freeman C, Adewumi A, La Caze A. A scoping review of health system guidelines for pharmacist responsibilities when dispensing opioids. Explor Res Clin Soc Pharm. 2023;27;12:100382.
34. Utah Department of Health, Utah Medical Association. Current Opioid Misuse Measure (COMM). Available at https://www.utahmed.org/Common/Uploaded%20files/Docs/CS_Resources/COMM%20-%20Current%20Opioid%20Misuse%20Measure.pdf. Last accessed August 1, 2025.
35. Janssen Pharmaceutica Products, LC. Pain Assessment and Documentation Tool. Available at https://lhatrustfunds.com/assets/uploads/documents/09-Pain-Assessment-Documentation-Tool.pdf. Last accessed August 1, 2025.
36. U.S. Drug Enforcement Administration. Prescriptions: Questions and Answers. Available at https://www.deadiversion.usdoj.gov/faq/prescriptions-faq.html. Last accessed August 1, 2025.
37. Code of Federal Regulations. Title 21, Chapter II, Part 1306, General Information, §1306.05 Manner of Issuance of Prescriptions. Available at https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR1eb5bb3a23fddd0/section-1306.05. Last accessed August 12, 2022.
38. Code of Federal Regulations. Title 21, Chapter II, Part 1306, General Information, §1306.11 Requirement of Prescription. Available at https://www.ecfr.gov/current/title-21/chapter-II/part-1306/subject-group-ECFR8588b52940237ef/section-1306.11. Last accessed August 1, 2025.
39. Opioid Analgesics REMS Program Companies. Patient Counseling Guide: What You Need to Know About Opioid Pain Medicines. Available at https://www.opioidanalgesicrems.com/Resources/Docs/patient_counseling_document.pdf. Last accessed August 1, 2025.
40. U.S. Food and Drug Administration. Where and How to Dispose of Unused Medicines. Available at https://www.fda.gov/consumers/consumer-updates/where-and-how-dispose-unused-medicines. Last accessed August 1, 2025.
41. U.S. Food and Drug Administration. Drug Disposal: FDA's Flush List for Certain Medicines. Available at https://www.fda.gov/drugs/disposal-unused-medicines-what-you-should-know/drug-disposal-fdas-flush-list-certain-medicines. Last accessed August 1, 2025.
42. Centers for Disease Control and Prevention. Cannabis and Chronic Pain. Available at https://www.cdc.gov/cannabis/health-effects/chronic-pain.html. Last accessed August 21, 2025.
43. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
44. World Health Organization. Medication Safety in Polypharmacy. Available at https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf. Last accessed August 1, 2025.
45. U.S. Food and Drug Administration. FDA's Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. Available at https://www.accessdata.fda.gov/drugsatfda_docs/rems/Opioid_analgesic_2018_09_18_FDA_Blueprint.pdf. Last accessed August 1, 2025.
46. U.S. Food and Drug Administration. FDA is requiring opioid pain medicine manufacturers to update prescribing information regarding long-term use. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-opioid-pain-medicine-manufacturers-update-prescribing-information-regarding-long-term. Last accessed August 1, 2025.
47. United States Census Bureau. U.S. Older Population Grew From 2010 to 2020 at Fastest Rate Since 1880 to 1890. Available at https://www.census.gov/library/stories/2023/05/2020-census-united-states-older-population-grew.html. Last accessed August 1, 2025.
48. Guerriero F. Guidance on opioids prescribing for the management of persistent non-cancer pain in older adults. World J Clin Cases. 2017 16;5(3):73-81.
49. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. Available at https://www.samhsa.gov/data/sites/default/files/reports/rpt56287/2024-nsduh-annual-national-report.pdf. Last accessed August 1, 2025.
50. Legislative Analysis and Public Policy Association. Drug Diversion in Health Care Fact Sheet. Available at https://legislativeanalysis.org/wp-content/uploads/2023/06/Healthcare-Diversion-Fact-Sheet-FINAL.pdf. Last accessed August 1, 2025.
51. Fan M, Tscheng D, Hamilton M, Hyland B, Reding R, Trbovich P. Diversion of controlled drugs in hospitals: a scoping review of contributors and safeguards. J Hosp Med. 2019;14(7):419-428.
52. Sekhon R, Aminjavahery N, Davis CN Jr, et al. Compliance with opioid treatment guidelines for chronic non-cancer pain (CNCP) in primary care at a Veterans Affairs Medical Center (VAMC). Pain Med. 2013;14(10):1548-1556.
53. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.
54. Holliday S, Hayes C, Dunlop A. Opioid use in chronic non-cancer pain. Part 2: prescribing issues and alternatives. Aust Fam Physician. 2013;42:104-111.
55. American Society of Health-System Pharmacists. ASHP Guidelines on Preventing Diversion of Controlled Substances. Available at https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/preventing-diversion-of-controlled-substances.pdf. Last accessed August 1, 2025.
56. American Medical Association. Code of Ethics: Opinion 1.1.5 Terminating a Patient-Physician Relationship. Available at https://code-medical-ethics.ama-assn.org/ethics-opinions/terminating-patient-physician-relationship. Last accessed August 1, 2025.
57. U.S. Department of Justice Drug Enforcement Administration, Diversion Control Division. Theft/Loss Reporting. Available at: https://www.deadiversion.usdoj.gov/21cfr_reports/theft/theft-loss.html. Last accessed August 1, 2025.
58. Louisiana Administrative Code. Title 46: Professional and Occupational Standards. Part XLV: Medical Professions. Available at https://www.doa.la.gov/media/japawb11/46v45.pdf. Last accessed August 1, 2025.
59. Centers for Disease Control and Prevention. Risk for overdose from methadone used for pain relief—United States, 1999–2010. MMWR. 2012;61(26):493-497.
60. U.S. Drug Enforcement Administration. Drug Scheduling. Available at https://www.dea.gov/drug-information/drug-scheduling. Last accessed August 1, 2025.
61. U.S. Drug Enforcement Administration. Controlled Substances, Alphabetical Order. Available at https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf. Last accessed August 1, 2025.
62. Louisiana Board of Medical Examiners. Information for CDS Prescribers RE: Act 76 of the 2017 Regular Session of the Louisiana Legislature. Available at https://a.storyblok.com/f/150540/3694d541d5/guidance-re-act-76.pdf. Last accessed August 1, 2025.
63. Louisiana State Legislature. 2017 Regular Session: Act No. 82. Available at https://www.legis.la.gov/legis/ViewDocument.aspx?d=1050996. Last accessed August 1, 2025.
64. U.S. Department of Justice. Drug Enforcement Administration. Diversion Control Division. ARCOS Retail Drug Summary Reports. Available at https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/arcos-drug-summary-reports.html. Last accessed August 1, 2025.
65. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS). Available at https://www.samhsa.gov/data/data-we-collect/teds-treatment-episode-data-set. Last accessed August 1, 2025.
66. Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System: Mortality Statistics. Available at https://www.cdc.gov/nchs/nvss/deaths.htm. Last accessed August 1, 2025.
67. RADARS System. Available at https://www.radars.org. Last accessed August 1, 2025.
68. Louisiana Board of Pharmacy. Prescription Monitoring Program (PMP) Information. Available at https://www.pharmacy.la.gov/page/prescription-monitoring-program-pmp-information. Last accessed August 1, 2025.
69. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text rev. Washington, DC: American Psychiatric Association; 2022.
70. van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635-646.
71. Kaye AD, Gevirtz C, Bosscher HA, et al. Ultrarapid opiate detoxification: a review. Can J Anaesth. 2003;50(7):663-671.
72. Xi ZX, Stein EA. GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol. 2002;37(5):485-494.
73. Harris AC, Gewirtz JC. Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal. Psychopharmacology (Berl). 2005;178(4):353-366.
74. National Institute on Drug Abuse. Screening and Assessment Tools Chart. Available at https://www.drugabuse.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools. Last accessed August 1, 2025.
75. National Institute on Drug Abuse. Tobacco, Alcohol, Prescription Medication, and Other Substance use Tool (TAPS). Available at https://nida.nih.gov/taps2. Last accessed August 1, 2025.
76. Substance Abuse and Mental Health Services Administration. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Available at https://www.samhsa.gov/substance-use/treatment/sbirt. Last accessed August 1, 2022.
77. Centers for Disease Control and Prevention. Lifesaving Naloxone. Available at https://www.cdc.gov/stop-overdose/caring/naloxone.html. Last accessed August 1, 2025.
78. Louisiana Department of Health. Standing Order for the Distribution or Dispensing of Naloxone or Other Opioid Antagonists. Available at https://ldh.la.gov/assets/HealthyLa/Pharmacy/NaloxoneStandingOrder.pdf. Last accessed August 1, 2025.
79. U.S. Department of Health and Human Services. Naloxone: The Opioid Reversal Drug That Saves Lives. Available at https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf. Last accessed August 1, 2025.
80. American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder, 2020 Focused Update. Available at https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline. Last accessed August 1, 2025.
81. Jain N, Chavan BS, Sidana A, Das S. Efficacy of buprenorphine and clonidine in opioid detoxification: a hospital-based study. Indian J Psychiatry. 2018;60(3):292-299.
82. Dunn KE, Tompkins DA, Bigelow GE, Strain EC. Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):885-893.
83. Doughty B, Morgenson D, Brooks T. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal. Ann Pharmacother. 2019;53(7):746-753.
84. Jordan CJ, Cao J, Newman AH, Xi ZX. Progress in agonist therapy for substance use disorders: lessons learned from methadone and buprenorphine. Neuropharm. 2019;158:107609.
85. Heinzerling KG, Ober AJ, Lamp K, De Vries D, Watkins KE. SUMMIT: Procedures for Medication-Assisted Treatment of Alcohol or Opioid Dependence in Primary Care. Available at https://www.rand.org/content/dam/rand/pubs/tools/TL100/TL148-1/RAND_TL148-1.pdf. Last accessed August 1, 2025.
86. Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol Tip 63. Available at https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf. Last accessed August 12, 2022.
87. Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med. 2004;164(3):277-288.
88. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006;43(Suppl 4):S173-S177.
89. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207-225.
90. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2020. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2021.
91. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA. 2008;300(19):2303-2305.
92. Srivastava A. Primary care management of opioid use disorders. Can Fam Physician. 2017;63(3):200-205.
93. Humphreys K, Wing S, McCarty D, et al. Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Substance Abuse Treat. 2004;26(3):151-165.
94. Ronel N, Gueta K, Abramsohn Y, Caspi N, Adelson M. Can a 12-step program work in methadone maintenance treatment? Int J Offender Ther Comp Criminol. 2011;55(7):1135-1153.
95. Stoops WW, Lile JA, Glaser PE, Hays LR, Rush CR. Alternative reinforcer response cost impacts cocaine choice in humans. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):189-193.
96. Donovan DM, Ingalsbe MH, Benbow J, Daley DC. 12-step interventions and mutual support programs for substance use disorders: an overview. Soc Work Public Health. 2013;28(3-4):313-332.
97. Jordan JB. Acupuncture treatment for opiate addiction: a systematic review. J Subst Abuse Treat. 2006;30(4):309-314.
98. Otto KC. Acupuncture and substance abuse: a synopsis, with indications for further research. Am J Addict. 2003;12(1):43-51.
99. Motlagh FE, Ibrahim F, Rashid RA, Seghatoleslam T, Habil H. Acupuncture therapy for drug addiction. Chin Med. 2016;11:16.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.